2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 704

Evaluating The Effects Of Combination Aspirin and Dipyridamole (asasantin retard) On Platelet Function, Oxidative Stress and Peripheral Vascular Function In Primary Raynaud’s Phenomenon and Systemic Sclerosis
Abstract Number: 321

Evaluation and Comparison Of Performance Of Different Classification Criteria For Reactive Arthritis
Abstract Number: 2352

Evaluation and Management Of Laboratory Abnormalities During Tocilizumab Treatment Either As Monotherapy Or In Combination With Dmards In RA Patients: Findings From The ACT-STAR Study
Abstract Number: 1505

Evaluation Of a Case Ascertainment Tool For Ankylosing Spondylitis and Axial Spondylarthritis Among All Referrals To General Rheumatology Clinics
Abstract Number: 2097

Evaluation Of An Advanced Practice Physiotherapist Role in Rheumatology
Abstract Number: 2353

Evaluation Of An Irreversible Dual Target Inhibitor (AC0025) Of Bruton’s Tryosine Kinase and Janus Kinase 3 As a Therapeutic Agent For Rheumatoid Arthritis
Abstract Number: 2624

Evaluation of Asymptomatic Venous Disease By Venous Doppler Ultrasonography in Patients With Behcet’s Disease
Abstract Number: 1360

Evaluation Of Biomarkers Involved In Periondontal Disease Including Porphyromonas Gingivalis Antibodies To Predict Response To Infliximab In Rheumatoid Arthritis Patients
Abstract Number: 451

Evaluation Of Disease Activity By The Routine Assessment Of Patient Index Data 3 In Patients With Rheumatoid Arthritis Receiving Tocilizumab
Abstract Number: 204

Evaluation Of Hospitalizations and Costs In Patients With Rheumatoid Arthritis In United States Medicare Population
Abstract Number: 2664

Evaluation Of Osteoporosis Medication Starts In Patients Based On T-Score and FRAX® Absolute Fracture Risk Model In a Large Health Care System
Abstract Number: 1369

Evaluation Of Porphyromona Gingivalis Serology In Rheumatoid Arthritis and Non-Rheumatoid Inflammatory Disease
Abstract Number: 1264

Evaluation Of Quality Indicators and Disease Damage In Childhood-Onset Systemic Lupus Erythematosus Patients
Abstract Number: 2821

Evaluation Of Selective Manipulation Of The CD28 Co-Stimulation Pathway In The Rhesus Monkey Model Of Collagen-Induced Arthritis
Abstract Number: 2607

Evaluation Of The Construct Validity Of The Patient-Reported Outcomes Measurement Information System (PROMIS®) Gastrointestinal (GI) Symptoms Measures In Systemic Sclerosis (SSc)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].